Zydus and Bioeq partner for commercialisation of Nufymco in US

Core Insights - Zydus Lifesciences Global FZE has partnered with Bioeq for the US commercialization of Nufymco, an interchangeable biosimilar of Lucentis (Ranibizumab), following FDA approval of its Biologics License Application [1][2] Group 1: Partnership Details - Under the agreement, Bioeq will manage development, manufacturing, registration, and supply of Nufymco, while Zydus will focus on its commercialization in the US market [2] - The partnership aims to leverage combined expertise and resources to enhance organizational growth and provide affordable ophthalmology care to patients [3] Group 2: Strategic Goals - Zydus will utilize its extensive distribution network and strong sales and marketing capabilities to expand treatment options for patients [4] - The collaboration is designed to drive innovation and improve healthcare accessibility, reflecting a commitment to delivering high-quality, affordable therapies [4]